Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies

Journal of Gene Medicine

Volumn 9, Issue 1, 2007, Pages 10-21

  Leung, Kitty ^a   Louca, Emily ^a   Munson, Keith ^b   Dutzar, Benjamin ^b   Anklesaria, Pervin ^b   Coates, Allan L ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Targeted Genetics Corporation   (United States)

^c Hospital for Risk Children   (Canada)

Author keywords

Aerosol; Cystic fibrosis; Lung gene therapy

Indexed keywords

PARVOVIRUS VECTOR; SALBUTAMOL;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; BREATHING PATTERN; CASE REPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG ACCUMULATION; DRUG STABILITY; HUMAN; LASER DIFFRACTION; MATHEMATICAL ANALYSIS; MEDICAL NEBULIZER; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCHOOL CHILD; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOCAL CORD;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; CYSTIC FIBROSIS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; LASERS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

ADENO-ASSOCIATED VIRUS;

EID: 33846821729     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.987     Document Type: Article

References (28)

1. Moss RB, Rodman D, Spencer T, et al. Repeated AAV2 aerosol-mediated CFTR gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2003; 125: 509-521.
2. Tsui L-C. The cystic fibrosis transmembrane conductance regulator gene. Am J Respir Crit Care Med 1995; 151: S47-S53.
3. Knowles MR, Olivier K, Noone P, et al. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis. Am J Respir Crit Care Med 1995; 151: S65-S69.
4. Clay MM, Pavia D, Newman SP, et al. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983; 38: 755-759.
5. Newman SP, Pellow PGD, Clay MM, et al. Evaluation of jet nebulisers for use with gentamycin solution. Thorax 1985; 40: 671-676.
6. Coates AL, MacNeish CF, Dinh L, et al. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000; 13: 169-178.
7. Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28-33.
8. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailablility of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-226.
9. Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7: 2185-2191.
10. Janssens HM, Jongste JC, Fokkens WJ, et al. The Sophia anatomical infant nose-throat Saint) model: A valuable tool to study aerosol deposition in infants. J Aerosol Med 2001; 14: 433-441.
11. Kwong WTJ, Ho SL, Coates AL. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med 2000; 13: 303-314.
12. Keller M, Lintz F-C, Walther E, et al. Effect of novel pharmaceutical formulation on nebulisation efficiency of an air jet and new electronic nebuliser. J Aerosol Med 2003; 14: 390 (Abstract).
13. Barry PW, O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol 1999; 104: 1168-1173.
14. Byrne NM, Keavey PM, Perry JD, et al. Comparision of lung deposition of colomycin using the HaloLite and Pari LC Plus nebulizers in patients with cystic fibrosis. Arch Dis Child 2003; 88: 715-718.
15. Alderson PO, Secker-Walker RH, Strominger DB, et al. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr 1974; 84: 479-484.
16. Brown JS, Zeman KL, Bennett WD. Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med 2001; 14: 443-454.
17. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis 1987; 136: 1445-1449.
18. Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115: 69-78.
19. Marple VA, Roberts DL, Romay FJ, et al. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). 1. Design. J Aerosol Med 2003; 16: 283-299.
20. Leung K, Louca E, Grey M, et al. Use of the new generation pharmaceutical impactor for particle size distribution measurements of live biological aerosols. J Aerosol Med 2005; 18: 414-426.
21. Atkinson EM, Debelak EM, Hart LA, et al. A high-throughput hybridization method for titer determination of viruses and gene therapy vectors. Nucleic Acids Res 1998; 26: 2821-2823.
22. Schwarz LA, Johnson JL, Black M, et al. Delivery of DNA-cationic liposme complexes by small-particle aerosol. Hum Gene Ther 1996; 7: 731-741.
23. Mukhopadhyay S, Staddon GE, Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994; 88: 203-211.
24. Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow and the addition of Ventolin respiratory solution affects tobramycin aerosols used in cystic fibrosis. Chest 1997; 111: 1206-1212.
25. MacNeish CF, Meisner D, Thibert R, et al. A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) respirator solution. Chest 1997; 111: 204-208.
26. Ho SL, Kwong WTJ, Coates AL. Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med 2001; 14: 467-475.
27. Hinds WC. Particle Size Statistics. Aerosol Technology: Properties, Behaviour, and Measurements of Airborne Particles, John Wiley: Chichester, 1982; 69-103.
28. Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16: 63-68.